CD40 ligand + interleukin-2 plasmid vaccine

The CD40 ligand + interleukin-2 plasmid vaccine is an investigational autologous tumor vaccine developed for the treatment of chronic lymphocytic leukemia (CLL). This therapeutic approach involves the ex vivo genetic modification of a patient's own leukemia cells using plasmid DNA electroporation. The vaccine is designed to introduce genes encoding CD40 ligand (CD40L) and interleukin-2 (IL-2) into the CLL cells. CD40L expression is intended to enhance the immunogenicity of the leukemia cells by upregulating co-stimulatory molecules (such as CD80 and CD86) and adhesion molecules (such as CD54), effectively converting the tumor cells into potent antigen-presenting cells. Simultaneously, the secretion of IL-2 serves to stimulate the activation and expansion of leukemia-reactive T cells. Clinical research has compared this plasmid-based delivery method to adenoviral vector delivery, noting that while plasmid transduction can lead to higher IL-2 secretion, it often results in lower CD40L expression and a less robust Th1-polarized immune response compared to adenoviral methods, which has been associated with differences in progression-free survival in clinical trials.

Other names

CD40L/IL-2 plasmid vaccineautologous CLL tumor vaccine (plasmid-transduced)